Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.543
Sell
RSI(14)
29.011
Sell
STOCH(KDJ)(9,3,3)
14.982
Sell
ATR(14)
2.607
High Vlolatility
CCI(14)
-122.776
Sell
Williams %R
95.650
Oversold
TRIX(12,20)
-0.680
Sell
StochRSI(14)
0.000
Oversold
Praxis Precision Medicines Inc
PRAX37.705USD
-1.715-4.35%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
793.33MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
101.000
Target Price
+156.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.55M.
Fairly Valued
The company’s latest PE is -3.04, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.03M shares, decreasing 3.61% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.45M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-12The company's current financial score is 6.42, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 75.20%.
Score
Financials
6.95
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.21
Operational Efficiency
2.67
Growth Potential
8.17
Shareholder Returns
7.11
Company Valuation
Currency: USD Updated：2025-09-12The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -3.78, which is -82.76% below the recent high of -0.65 and -49.44% above the recent low of -5.66.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 81/507
No Data
Earnings Forecast
Currency: USD Updated：2025-09-12The company’s current earnings forecast score is 8.17, which is higher than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Praxis Precision Medicines Inc is 82.50, with a high of 270.00 and a low of 33.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
13
analysts
Buy
Current Rating
101.000
Target Price
+156.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
555
Total
5
Median
6
Average
Company name
Ratings
Analysts
Praxis Precision Medicines Inc
PRAX
13
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
26
Intellia Therapeutics Inc
NTLA
26
Exact Sciences Corp
EXAS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-12The company’s current price momentum score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 54.36 and the support level at 41.81, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
39.627
Sell
MA10
42.811
Sell
MA20
44.739
Sell
MA50
48.933
Sell
MA100
44.508
Sell
MA200
52.880
Sell
Institutional Confidence
Currency: USD Updated：2025-09-12The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 119.12%, representing a quarter-over-quarter increase of 1.50%. The largest institutional shareholder is PRFDX, holding a total of 1.45M shares, representing 6.87% of shares outstanding, with 8.20% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Janus Henderson Investors
Adage Capital Management, L.P.
Cormorant Asset Management, LP
BlackRock Institutional Trust Company, N.A.
Perceptive Advisors LLC
Soleus Capital Management, L.P.
Morgan Stanley & Co. LLC
1
2
Risk Assessment
Currency: USD Updated：2025-09-12The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.10, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 2.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.63
VaR
+8.11%
240-Day Maximum Drawdown
+68.64%
240-Day Volatility
+91.72%
Return
Best Daily Return
60 days
+7.81%
120 days
+13.29%
5 years
+24.96%
Worst Daily Return
60 days
-13.02%
120 days
-13.02%
5 years
-78.11%
Sharpe Ratio
60 days
-0.57
120 days
+0.38
5 years
+0.05
Risk Assessment
Maximum Drawdown
240 days
+68.64%
3 years
+83.86%
5 years
+98.67%
Return-to-Drawdown Ratio
240 days
-0.47
3 years
+0.19
5 years
-0.19
Skewness
240 days
-2.58
3 years
-1.81
5 years
-2.50
Volatility
Realised Volatility
240 days
+91.72%
5 years
+113.94%
Standardised True Range
240 days
+9.48%
5 years
+30.26%
Downside Risk-Adjusted Return
120 days
+54.93%
240 days
+54.93%
Maximum Daily Upside Volatility
60 days
+50.17%
Maximum Daily Downside Volatility
60 days
+53.76%
Liquidity
Average Turnover Rate
60 days
+2.07%
120 days
+2.10%
5 years
--
Turnover Deviation
20 days
-2.71%
60 days
-15.43%
120 days
-14.23%
Peer Comparison
Currency: USD Updated：2025-09-12Praxis Precision Medicines Inc
PRAX
5.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insmed Inc
INSM
7.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Protagonist Therapeutics Inc
PTGX
7.04 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
